3SBio Inc. Acquires Control Of CP Guojian In $213 Million Deal
3SBio of Shenyang expanded its biosimilar business by raising its stake in Shanghai CP Guojian Pharma to 54%. 3SBio, which acquired 7% of Guojian last year, paid $213 million for 47% of Guojian's outstanding shares. Guojian has two biosimilar products on the market: Yisaipu, a biosimilar to Amgen's Enbrel anti-inflammatory drug, and Xenopax, a biosimilar to Biogen's Zinbryta anti-organ rejection treatment. In addition, Guojian has a portfolio of mAbs awaiting CFDA approval and a mAb manufacturing facility.